Hilo

Key People

• Raghav 'Rags' Gupta - Co-Founder & CEO
• Josep Sola - Co-Founder & CTO
• Mattia Bertschi - Co-Founder & COO
• Neil Puri - Head of Quality and Regulatory Affairs

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in biomedical engineering and telecommunications, contributing to over 120 peer-reviewed publications and holding more than 35 patents.

The co-founders' prior experience at the Swiss research institute CSEM and their contributions to numerous publications and patents demonstrate a strong foundation in biomedical signal processing and clinical research, essential for advancing Hilo's mission.

Clinical Need

Aspect: Very Strong
Summary: Hypertension affects over 1.3 billion people globally, with only 20% having their blood pressure under control, highlighting a significant unmet need for innovative monitoring solutions.

The prevalence of uncontrolled hypertension underscores the necessity for accessible and accurate monitoring tools. Hilo's cuffless blood pressure monitoring technology offers a convenient solution to this widespread health issue.

Competition

Aspect: First mover
Summary: Hilo is the first company to receive FDA clearance for an over-the-counter cuffless blood pressure monitor, positioning it ahead of competitors in the market.

As the pioneer in FDA-cleared cuffless blood pressure monitoring, Hilo has the opportunity to set industry standards and capture market share before competitors enter the space.

Technical Challenge

Aspect: Very Complex
Summary: Developing accurate cuffless blood pressure monitoring involves sophisticated AI algorithms and extensive datasets, presenting significant technical challenges.

Hilo's development of a machine learning model trained on billions of optical signals and hundreds of millions of readings demonstrates their capability to overcome these technical challenges.

Patent

Aspect: Very Strong
Summary: Hilo holds over 35 patents related to its cuffless blood pressure monitoring technology, providing robust intellectual property protection.

The extensive patent holdings safeguard Hilo's innovations, deterring competitors and supporting long-term business viability.

Financing

Aspect: Strategics
Summary: Hilo has secured over $100 million in funding, including a $42 million Series B round co-led by prominent investors.

The financial backing from reputable investors enables Hilo to accelerate product development, expand into new markets, and enhance its blood pressure intelligence platform.

Regulatory

Aspect: 510k/PMA + Reimbursement
Summary: Hilo has achieved FDA 510(k) clearance for over-the-counter use and secured regulatory approvals in multiple countries.

The FDA clearance and international approvals facilitate Hilo's entry into key markets, ensuring adherence to regulatory standards and enhancing credibility among consumers and healthcare professionals.

Opportunity Rollup

Odds of Success

2.6

Peak Market Share

2.85

Segment CAGR

3.6%

Market Segment

Patient Monitoring

Market Sub Segment

Cuffless Blood Pressure Monitoring

Key Takeaway

Hilo's innovative cuffless blood pressure monitoring technology, backed by a strong team and substantial funding, positions it well to address the global hypertension crisis and capitalize on the growing wearable health tech market.